This issue of Rheumatic Disease Clinics, guest edited by Drs. Andrew Bomback and Meghan Sise, will cover several key aspects of Renal Involvement in Rheumatic Diseases. The Consulting Editor for the series is Dr. Michael Weisman. The topics discussed in the issue will include: ANCA, Lupus GN, proliferative and non-proliferative, Renal manifestations of RA, Secondary amyloidosis, Nephrotoxicity of select rheumatology drugs, Acute and chronic TI nephritis, rheumatology etiologies, TMAs with rheum etiologies, Anti-GBM, Autoimmune manifestations of viral infections, and Renal manifestations of IBD, among others.

This issue of Rheumatic Disease Clinics, guest edited by Drs. James Katz and Brian Walitt with the NIH, will cover several key aspects of diagnosing and treating Rheumatic Diseases in Older Adults. The Consulting Editor for the series is Dr. Michael Weisman. The topics discussed in the issue will include: Pharmacotherapy Pearls for the Geriatrician, Pathogenesis and Management of Sarcopenia, A Review of Osteoporosis in the Older Adult, Regional Rheumatic Disorders and Rehabilitation in Older Adults, Rheumatologic Manifestations of Malignancy, Sjögren Syndrome and Other Causes of Sicca in Older Adults, Cardiovascular Disease Risk in Patients with Rheumatic Diseases, Update on Crystal-Induced Arthritides, Immune dysregulation in aging with a focus on B cells and their potential clinical consequence, and Spinal Stenosis, among others.

This issue of Rheumatic Disease Clinics, guest edited by Dr. John Davis, will discuss Cancer and Rheumatic Diseases. This issue is one of four selected each year by series Consulting Editor, Dr. Michael Weisman. Topics discussed in this issue include, but are not limited to: rheumatic drugs and malignancy potential, biologic drugs and cancer, methotrexate and cancer, managing rheumatoid arthritis with cancer, Sjogren's Syndrome and cancer, lupus and cancer, scleroderma and cancer, cancer and spondylarthritis, and cancer immunotherapy.

Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.

In this issue of Rheumatic Disease Clinics, guest editor Dr. Erin Janssen brings her considerable expertise to the topic of New and Emerging Rheumatic Diseases. Top experts in the field cover issues such as approach to diagnosing in-born errors of immunity; Type I interferonopathies; SOCS1 and immune dysregulation; manifestations of DADA2; COPA syndrome; and more. - Contains 15 relevant, practice-oriented topics including T cell tolerance/Treg defects; gene defects in early onset IBD/colitis; autoimmunity with cytoskeletal d/o - WAS, DOCK8; autoimmune and autoinflammatory neurologic conditions; genes in HLH and that predispose to MAS; mutations in severe COVID/MISC; and more. - Provides in-depth clinical reviews on new and emerging rheumatic diseases, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Guest edited by Drs. Jeffrey Curtis, Kevin Winthrop and Kaleb Michaud, this issue of Rheumatic Disease Clinics will cover several key areas of interest related to Technology and Big Data in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles in this issue include, but are not limited to: Adherence & Adverse Event Ascertainment through mHealth; Digital Patient Education and Decision Aids; Imaging in the mobile domain; Quality Measures made easier with mHealth data; Patient self-management and tracking; Motivational Counseling and SMS Reminders; Digital Interventions to build community support; Telehealth to solve cases in under-resourced areas; Trials, eConsents, Data Linkage & the Future; Clinical experience with devices; and PROMIS vs legacy data instruments.

In this first-of-its-kind issue of Rheumatic Disease Clinics, guest editor Dr. Bryant R. England brings his considerable expertise to the topic of Environmental Triggers for Rheumatic Diseases. In practical, state-of-the-art articles, top experts examine the connection between some of the most commonly seen rheumatic disease and environmental triggers for the disease. - Contains 13 practice-oriented topics including inhalant and mucosal-related environmental risks for rheumatoid arthritis; lifestyle, hormonal, and microbial-related environmental risks for rheumatoid arthritis; environmental risks for systemic lupus erythematosus; environmental risks for osteoarthritis; targeting environmental risks to prevent rheumatic diseases; and more. - Provides in-depth clinical reviews on environmental triggers for rheumatic diseases, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.